Subsequent Event

3 Months Ended

Mar. 31, 2016

Subsequent Event [Abstract]

Subsequent Event [Text Block]

Note 12.  Subsequent Event

On April 28, 2016, we entered into an agreement with a subsidiary of Bayer, pursuant to which we granted Bayer exclusive worldwide rights to develop and commercialize products using our PSMA antibody technology in combination with Bayer's alpha-emitting radionuclides. Under this agreement, we will receive an upfront payment of $4 million and could receive up to an additional $49 million in potential clinical and regulatory development milestones. We are also entitled to single digit royalties on net sales, and potential net sales milestone payments up to an aggregate total of $130 million.